alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          OCT-31-1997
<PERIOD-START>                             NOV-01-1996
<PERIOD-END>                               OCT-31-1997
<CASH>                                             129
<SECURITIES>                                         0
<RECEIVABLES>                                    2,778
<ALLOWANCES>                                        27
<INVENTORY>                                         47
<CURRENT-ASSETS>                                 3,102
<PP&E>                                           3,695
<DEPRECIATION>                                   2,733
<TOTAL-ASSETS>                                   4,707
<CURRENT-LIABILITIES>                            2,309
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        23,291
<OTHER-SE>                                    (21,071)
<TOTAL-LIABILITY-AND-EQUITY>                     4,707
<SALES>                                         12,736
<TOTAL-REVENUES>                                12,736
<CGS>                                            5,337
<TOTAL-COSTS>                                   12,628
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  21
<INCOME-PRETAX>                                     87
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                 87
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                        87
<EPS-PRIMARY>                                     0.01
<EPS-DILUTED>                                     0.01
        

</TABLE>
STAKEHOLDER ANNOUNCEMENT

USDA Invites Comments on Changes to Expand Eligibility for Tribes Under the 

Rural Business Development Grants Program

WASHINGTON, May 24, 2023 – U.S. Department of Agriculture (USDA) Rural Development Under 

Secretary Xochitl Torres Small today announced that USDA is inviting comments on a proposal to expand 

eligibility for Tribes under the Rural Business Development Grants program.

These grants create jobs, spur economic growth and support enterprise projects in rural and Tribal communities. 

The changes USDA is proposing will expand eligibility definitions under the program to enable more Tribal 

government-owned entities to qualify for funding.

For instance, the Department plans to:

• Expand the “Small and Emerging Business” definition to include Tribal governments and Tribal-owned

entities.

• Clarify the definition for “Conflict of Interest” to explain how the agency defines the relationship 

between Tribal nations and their Tribal-owned entities.

USDA will also host a virtual Tribal Consultation on this proposed rule during the open comment period. 

Additional details are forthcoming.

Comments must be submitted at www.regulations.gov by July 24, 2023.

For more information, visit page 33552 of the May 24 Federal Register.

To subscribe to USDA Rural Development updates, visit GovDelivery subscriber page.

###

USDA is an equal opportunity provider, employer, and lender.
23456789101112131415161718192021222324
II

106TH CONGRESS

1ST SESSION S. 1157

To repeal the Davis-Bacon Act and the Copeland Act.

IN THE SENATE OF THE UNITED STATES

MAY 27, 1999

Mr. SMITH of New Hampshire (for himself, Mr. INHOFE, Mr. THURMOND,

Mr. NICKLES, Mr. HELMS, and Mr. COCHRAN) introduced the following

bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To repeal the Davis-Bacon Act and the Copeland Act.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. DAVIS-BACON ACT.

4 (a) REPEAL.—The Act of March 3, 1931 (40 U.S.C.

5 276a et seq.) (commonly referred to as the Davis-Bacon

6 Act) is repealed.

7 (b) REFERENCES.—Any reference in any law to a

8 wage requirement of the Act of March 3, 1931, shall after

9 the date of the enactment of this Act be null and void.
2

•S 1157 IS

1 SEC. 2. COPELAND ACT.

2 Section 2 of the Act of June 13, 1934 (40 U.S.C.

3 276c) (commonly referred to as the ‘‘Copeland Act’’) is

4 repealed.

5 SEC. 3. EFFECTIVE DATE.

6 The amendments made by sections 1 and 2 shall take

7 effect 30 days after the date of the enactment of this Act

8 but shall not affect any contract in existence on such date

9 of enactment or made pursuant to invitation for bids out10 standing on such date of enactment.

Æ
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This  Schedule  contains  summary  financial  information  extracted  from Baron
Capital Properties, L.P.'s financial statements for the three months ended March
31,  2000 and is  qualified  in its  entirety  by  reference  to such  financial
statements.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                              DEC-31-2000
<PERIOD-END>                                   MAR-31-2000
<CASH>                                           128,636
<SECURITIES>                                           0
<RECEIVABLES>                                    299,643
<ALLOWANCES>                                           0
<INVENTORY>                                            0
<CURRENT-ASSETS>                                 428,279
<PP&E>                                         7,504,843
<DEPRECIATION>                                (1,488,141)
<TOTAL-ASSETS>                                 7,526,041
<CURRENT-LIABILITIES>                          1,174,408
<BONDS>                                        4,357,849
<PREFERRED-MANDATORY>                                  0
<PREFERRED>                                            0
<COMMON>                                               0
<OTHER-SE>                                     1,993,784
<TOTAL-LIABILITY-AND-EQUITY>                   7,526,041
<SALES>                                                0
<TOTAL-REVENUES>                                 255,368
<CGS>                                                  0
<TOTAL-COSTS>                                    255,368
<OTHER-EXPENSES>                                 199,516
<LOSS-PROVISION>                                       0
<INTEREST-EXPENSE>                                     0
<INCOME-PRETAX>                                 (224,886)
<INCOME-TAX>                                           0
<INCOME-CONTINUING>                                    0
<DISCONTINUED>                                         0
<EXTRAORDINARY>                                        0
<CHANGES>                                              0
<NET-INCOME>                                    (224,886)
<EPS-BASIC>                                         (.12)
<EPS-DILUTED>                                       (.12)



</TABLE>
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
COMPANY'S CONSOLIDATED BALANCE SHEETS, CONSOLIDATED STATEMENTS OF EARNINGS, AND
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS AS OF AND FOR THE FISCAL YEAR
ENDED OCTOBER 31, 1997 SHOWN ELSEWHERE IN THIS REPORT AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<RESTATED> 
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          OCT-31-1997
<PERIOD-END>                               OCT-31-1997
<CASH>                                         128,871
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             3,102,244
<PP&E>                                       3,694,924
<DEPRECIATION>                               2,732,749
<TOTAL-ASSETS>                               4,707,478
<CURRENT-LIABILITIES>                        2,309,437
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                    23,290,733
<OTHER-SE>                                  21,070,799
<TOTAL-LIABILITY-AND-EQUITY>                 4,707,478
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                  87,331
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    87,331
<EPS-PRIMARY>                                      .01
<EPS-DILUTED>                                      .01
        

</TABLE>
UNPUBLISHED

UNITED STATES COURT OF APPEALS 

FOR THE FOURTH CIRCUIT 

No. 09-6090

UNITED STATES OF AMERICA, 

 Plaintiff - Appellee, 

 v. 

MARK ANTHONY JACOBS, 

 Defendant - Appellant. 

Appeal from the United States District Court for the Middle 

District of North Carolina, at Greensboro. James A. Beaty, Jr., 

Chief District Judge. (2:97-cr-00136-WLO-1) 

Submitted: May 21, 2009 Decided: May 29, 2009 

Before MOTZ, TRAXLER, and AGEE, Circuit Judges. 

Affirmed by unpublished per curiam opinion. 

Mark Anthony Jacobs, Appellant Pro Se. Robert Michael Hamilton, 

Angela Hewlett Miller, Assistant United States Attorneys, 

Greensboro, North Carolina, for Appellee.

Unpublished opinions are not binding precedent in this circuit. 
2 

PER CURIAM: 

 Mark Anthony Jacobs appeals the district court’s order 

denying his motion for a reduction of sentence pursuant to 18 

U.S.C. § 3582(c) (2006). We have reviewed the record and find 

no reversible error. Accordingly, we affirm on the reasoning of 

the district court. United States v. Jacobs, No. 2:97-cr-00136-

WLO-1 (M.D.N.C. Dec. 12, 2008). We dispense with oral argument 

because the facts and legal contentions are adequately presented 

in the materials before the court and argument would not aid the 

decisional process. 

AFFIRMED
§ 311.9 Actinomycosis and actinobacillosis. ( a ) The definition of generalization as outlined for tuberculosis in § 311.2(a) shall apply for actinomycosis and actinobacillosis, and carcasses of livestock with generalized lesions of either such disease shall be condemned.
( b ) Carcasses of livestock in a well-nourished condition showing uncomplicated localized lesions of actinomycosis or actinobacillosis may be passed for human food after the infected organs or other infected parts have been removed and condemned, except as provided in paragraphs (c) and (d) of this section.
( c ) Heads affected with actinomycosis or actinobacillosis, including the tongue, shall be condemned, except that when the disease of the jaw is slight, strictly localized, and without suppuration, fistulous tracts, or lymph node involvement, the tongue, if free from disease, may be passed, or, when the disease is slight and confined to the lymph nodes, the head including the tongue, may be passed for human food after the affected nodes have been removed and condemned.
( d ) When the disease is slight and confined to the tongue, with or without involvement of the corresponding lymph nodes, the head may be passed for human food after removal and condemnation of the tongue and corresponding lymph nodes.
### §4405. Preemption

No stay, injunction, avoidance, moratorium, or similar proceeding or order, whether issued or granted by a court, administrative agency, or otherwise, shall limit or delay application of otherwise enforceable netting contracts in accordance with sections 4403 and 4404 of this title.

(Pub. L. 102–242, title IV, §405, Dec. 19, 1991, 105 Stat. 2375.)
### §3905. Disenrollment

Members of the Auxiliary may be disenrolled pursuant to applicable regulations.

(Aug. 4, 1949, ch. 393, 63 Stat. 555, §824; renumbered §3905, Pub. L. 115–282, title I, §119(b), Dec. 4, 2018, 132 Stat. 4236.)

#### Historical and Revision Notes

Experience has shown that it is desirable to have a statute definitely providing for separation of Auxiliarists from the organization. 81st Congress, House Report No. 557.

#### **Editorial Notes**

#### Amendments

2018—Pub. L. 115–282 renumbered section 824 of this title as this section.
-----Forwarded by Melanie King/RTP/USEPA/US on 02/15/2010 09:49PM -----

To: Melanie King/RTP/USEPA/US@EPA

From: "Rentz, Rebecca" <Rebecca.Rentz@bgllp.com>

Date: 01/28/2010 05:13PM

cc: "Holmstead, Jeff" <Jeff.Holmstead@bgllp.com>, "Wasson, Mike"

<Mike.Wasson@Exterran.com>, <JDutton@jwoperating.com>, <David.O'Leary@warrenequipment.com>

Subject: Rulemaking EPA-HQ-OAR-2008-0708

Melanie,

Please find attached SI Management Practice recommendations for your 

consideration. These

recommendations are being submitted on behalf of Exterran, JW Power Company 

and CSI (EJC) but

have also received input and support from others who operate SI RICE 

potentially impacted by the

proposed rule.

Please do not hesitate to contact us if you have any questions or need 

additional information.

Thank you,

Rebecca

Rebecca J Rentz | Counsel | Bracewell & Giuliani LLP

711 Louisiana Street, Suite 2300 | Houston, Texas | 77002-2770

T: 713.221.1176 | F: 713.221.2134

rebecca.rentz@bgllp.com | www.bgllp.com/rentz | www.bgllp.com
### §4207. Unreviewed declarations; petition to pursue action as private contractor

#### (a) Notification

(1) If, pursuant to section 4206(d)(2) of this title, the Attorney General notifies a declarant that the declarant's allegations have not yet been addressed, the declarant may notify the Attorney General to award a contract pursuant to subchapter III to pursue the case.

(2) A declarant's notification under paragraph (1) shall be filed with the Attorney General not later than 30 days after the date of service of notice under section 4206(d)(2) of this title, and the Attorney General shall respond to the notification not later than 30 days after receipt.

#### (b) Contents of response

In response to a notification under subsection (a)(1), the Attorney General shall—

(1) grant a contract pursuant to subchapter III; or

(2) proceed with an action.

#### (c) Grant of contract

If the Attorney General decides to grant a contract, the declarant, after consultation with the Attorney General, shall have the right to select counsel to prosecute an action, and the declarant and the declarant's counsel shall act in accordance with subchapter III.

(Pub. L. 101–647, title XXV, §2567, Nov. 29, 1990, 104 Stat. 4898.)
# C_2006297EN.01004801.xml

| 7.12.2006 | EN | Official Journal of the European Union | C 297/48 |
| --- | --- | --- | --- |

7.12.2006

EN

Official Journal of the European Union

C 297/48

---

Non-opposition to a notified concentration

(Case COMP/M.4242 — Thermo Electron/Fisher Scientific)

(Text with EEA relevance)

(2006/C 297/14)

On 9 November 2006, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(2) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website under document number 32006M4242. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu) |
| --- | --- |

—

in electronic form on the EUR-Lex website under document number 32006M4242. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu)

---
```

[Congressional Bills 106th Congress]
[From the U.S. Government Publishing Office]
[S. 133 Introduced in Senate (IS)]

106th CONGRESS
  1st Session
                                 S. 133

                 For the relief of Benjamin M. Banfro.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                            January 19, 1999

   Mr. Craig introduced the following bill; which was read twice and 
               referred to the Committee on the Judiciary

_______________________________________________________________________

                                 A BILL

 
                 For the relief of Benjamin M. Banfro.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. PERMANENT RESIDENCE.

    In the administration of the Immigration and Nationality Act (8 
U.S.C. 1101 et seq.), Benjamin M. Banfro shall be held and considered 
to have been lawfully admitted to the United States for permanent 
residence as of the date of the enactment of this Act upon payment of 
the required visa fees.

SEC. 2. REDUCTION OF NUMBER OF AVAILABLE VISAS.

    Upon the granting of permanent residence to Benjamin M. Banfro as 
provided in this Act, the Secretary of State shall instruct the proper 
officer to reduce by one number during the current fiscal year the 
total number of immigrant visas available to natives of the country of 
the alien's birth under subsection (a) of section 203 of the 
Immigration and Nationality Act (8 U.S.C. 1153).
                                 <all>
```
2005 年 9 月 28 日 第 1 頁,共 2 頁

情況說明書 

 

繁體中文 有關流行性感冒(流感)疫苗的重要情況 

Chinese translation of "Key Facts about Influenza (Flu) Vaccine”

(http://www.cdc.gov/flu/protect/keyfacts.htm) 

預防流感的唯一最佳方法就是每年秋季接種流感疫苗。

疫苗有兩種類型:

• 「流感注射」— 用針筒注射的去活性疫苗(含有被殺死的病毒),通常在手臂注射。流感注射被核准年齡超過 6 

個月以上的人士,包括健康人和罹患慢性疾病者。

• 鼻噴霧流感疫苗 — 由有活性的減毒流感病毒製做的疫苗,這種病毒不會引起流感(有時稱為 LAIV,即「活性減

毒流感疫苗」)。LAIV 被核准可用於 5 歲至 49 歲、沒有懷孕的健康人士。

每支疫苗都含有三種流感病毒 — 一種 A 型 (H3N2) 病毒、一種 A 型 (H1N1) 病毒和一種 B 型病毒。依據國際監督和科

學家對特定年份內將傳播哪種病毒型和病毒株的評估,疫苗中的病毒每年都有變化。

接種後大約兩週,會產生抗體並預防體內出現流感病毒感染。

什麼時候接種疫苗

十月或十一月是接種疫苗的最佳時間,但您也可以在十二月甚至更晚接種。流感季節能夠最早始於十月,並且能最久持續到

次年五月。

誰應當獲得接種

一般而言,希望減少罹患流感機會的任何人都應接種。但是,某些人士應每年都獲得接種。他們是發生嚴重流感併發症風險

高的人士,或是與嚴重併發症風險高者共同居住或提供照護的人士。 

應當每年獲得接種的人士包括:

1.) 流感併發症風險高的人士:

• 65 歲及以上的人士;

• 收容長期疾病患者的護理之家和其他長期照護機構內的住民;

• 罹患慢性心肺疾病(包括哮喘)的成年人和 6 個月及以上的兒童;

• 需要例行醫療照護,或曾在上一年因代謝性疾病(例如糖尿病)、慢性腎臟疾病或免疫系統功能衰弱(包括由藥物或因感染

人體免疫缺陷病毒 [HIV/愛滋病 ] 引起的免疫系統疾病)而住院治療的成年人,及年滿 6 個月及以上的兒童;

• 長期服用阿斯匹靈的 6 個月至 18 歲兒童。(在罹患流感時服用阿斯匹靈的兒童具有發生 Reye 症候群的風險);

• 將在流感季節懷孕的婦女;

• 6 至 23 個月的所有兒童;

• 罹患危害呼吸功能或呼吸道分泌物處理的任何疾病者(即會造成病人呼吸或吞嚥困難的疾病,例如大腦損傷或疾病、脊髓損

傷、癲癇,或其它神經或肌肉疾病。)

2.) 50 至 64 歲的人士。由於 50 至 64 歲的美國人中,有將近三分之一罹患會增加嚴重流感併發症風險的一種或多種疾

病,所以建議 50 至 64 歲的所有人士都接種疫苗。 
有關流感疫苗的重要情況 

(續前頁)

2005 年 9 月 28 日 第 2 頁,共 2 頁

3.) 會將流感傳播給併發症風險高者的人士。與高風險族群(如上所述)密切接觸的任何人都應當接種。這包括所有健康照

護工作人員、0 至 23 個月兒童的家庭人員和戶外照護提供者,以及與 65 歲及以上人士密切接觸者。

 

誰不應當接種

若干人士未向醫師諮詢前不應接種。他們包括:

• 對雞蛋嚴重過敏者。

• 曾經對流感疫苗發生嚴重反應者。

• 曾經在接種流感疫苗後 6 週內出現格林-巴利 (Guillain-Barré) 症候群 (GBS) 者。(請參閱

www.cdc.gov/flu/about/qa/gbs.htm。)

• 流感疫苗未被核准用於 6 個月以下的兒童。

• 罹患中度或嚴重疾病且發熱者,應當等到其症狀減輕後再進行接種。

疫苗的效力

流感疫苗的預防能力會依接種疫苗者的年齡和健康狀態,以及疫苗和傳播中的病毒株的相似性或「匹配度」而異。測試顯

示,兩種疫苗都能夠有效地預防流感。

疫苗的副作用(預期出現)

流感注射和 LAIV 可以有不同的副作用。

流感注射:流感注射中的病毒已經被殺死(去活性),因此您不會透過流感注射而罹患流感。可能出現的一些輕微副作用

包括:

• 注射部位疼痛、發紅或腫脹

• 發熱(低燒)

• 疼痛

如果出現這些問題,它們將在注射後很快出現,且通常持續一至兩天。幾乎所有接種流感疫苗者都不會因此出現嚴重問題。

但在極少情況下,疫苗可以引起嚴重問題,例如嚴重過敏反應。

LAIV:鼻噴霧疫苗中的病毒已被減毒,因此不會引起與流感有關的嚴重症狀。(在臨床研究中,疫苗病毒傳播至密切接觸

者非常罕見。)

LAIV 可能發生在兒童中的副作用包括:

• 流鼻涕

• 頭痛

• 嘔吐

• 肌肉痛

• 發熱

LAIV 可能發生在成人中的副作用包括:

• 流鼻涕

• 頭痛

• 喉嚨痛

• 咳嗽

For more information, visit www.cdc.gov/flu, or call CDC at 

800-CDC-INFO (English and Spanish) or 888-232-6358 (TTY).
#### § 2.26 Acknowledgment of regulations and standards.

APHIS will supply a copy of the regulations and standards in this subchapter with each registration form. The registrant shall acknowledge receipt of and shall agree to comply with the regulations and standards by signing a form provided for this purpose by APHIS, and by filing it with the Deputy Administrator.

(Approved by the Office of Management and Budget under control numbers 0579-0036 and 0579-0486)

[54 FR 36147, Aug. 31, 1989, as amended at 63 FR 62926, Nov. 10, 1998; 85 FR 28797, May 13, 2020; 88 FR 10713, Feb. 21, 2023]
### §§992 to 993. Repealed. Pub. L. 87–353, §3(a), (w), Oct. 4, 1961, 75 Stat. 773, 774

Section 992, act July 17, 1916, ch. 245, §32 (par.), as added May 12, 1933, ch. 25, title II, §21, 48 Stat. 41; amended June 16, 1933, ch. 98, title VIII, §80(a), 48 Stat. 273, related to Government guaranty of interest on qualified Federal land bank bonds issued during limited period, use of proceeds of such bonds, limitation on aggregate amount of such bonds, payment of interest by Government on inability of issuing bank and rights of Government after such payment.

Section 992a, act Jan. 31, 1934, ch. 7, §5, 48 Stat. 346, prohibited any Federal land bank, ninety days after January 31, 1934, from issuing any bonds under provisions of section 992 of this title, subject to guarantee of interest on such bonds by United States except for purpose of refinancing any bond which was or had been issued subject to such guarantee of interest.

Section 993, act July 17, 1916, ch. 245, §32 (par.), as added May 12, 1933, ch. 25, title II, §21, 48 Stat. 41, related to delivery of bonds issued under section 992 of this title in payment of certain mortgages.
Exhibit 99.4      CERTIFICATIONS UNDER SECTION 906 OF THE SARBANES-OXLEY
                  ACT OF 2002

Pursuant  to  Section  906 of the  Sarbanes-Oxley  Act of  2002,  each  of the
undersigned  certifies  that  this  annual  report  fully  complies  with  the
requirements of Section 13(a) or 15(d) of the Securities  Exchange Act of 1934
and that information contained in this annual report fairly represents, in all
material  respects,  the  financial  condition  and results of  operations  of
Frontline Ltd.

/s/ John Fredriksen
------------------------------
    John Fredriksen
    Chief Executive Officer and President


/s/ Tom E. Jebsen
------------------------------
    Tom E. Jebsen
    Chief Financial Officer


/s/ Kate Blankenship
------------------------------
    Kate Blankenship
    Chief Accounting Officer

Date: July  15, 2003
### §2731. Delegation of powers to make awards; rules and regulations

The President may delegate to the Secretary, under such conditions, regulations, and limitations as he prescribes, the powers conferred upon him to make the awards designated in this chapter, and the President may make any and all rules, regulations, and orders which he deems necessary in the conferring of such awards.

(Aug. 4, 1949, ch. 393, 63 Stat. 536, §499; renumbered §2731, Pub. L. 115–282, title I, §116(b), Dec. 4, 2018, 132 Stat. 4226.)

#### Historical and Revision Notes

This section provides for the delegation of powers to make awards to the Secretary. The Navy statute provides for such delegation to force commanders (see title 34, U.S.C., 1946 ed., §364). 81st Congress, House Report No. 557.

#### **Editorial Notes**

#### Amendments

2018—Pub. L. 115–282 renumbered section 499 of this title as this section.